GlassScriptPhysician profile
Steven L Nickles
NPI 1760483051
$5,197.33
in general payments reported to CMS, 2019-2025
36 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $369 · 2021: $630 · 2022: $749 · 2023: $563 · 2024: $490 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $735.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $709.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $464.52 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $340.85 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $311.97 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $261.70 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.44 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $227.37 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $217.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.59 | 2019-2025 | Xifaxan |
| Arbor Pharmaceuticals, INC. | $167.52 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $139.01 | 2019 | |
| Mannkind Corporation | $138.39 | 2019 | |
| Horizon Therapeutics Plc | $136.27 | 2019-2020 | |
| Novo Nordisk INC | $98.50 | 2021-2025 | Wegovy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $87.90 | 2019-2025 | Mounjaro, Zepbound |
| Genentech USA, INC. | $84.33 | 2019-2021 | |
| Astellas Pharma US INC | $81.09 | 2019 | |
| Gilead Sciences, INC. | $80.74 | 2022-2025 | |
| Exact Sciences Corporation | $75.80 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $39.72 | 2025 | Watchman Access System |
| Medtronic, INC. | $38.77 | 2023 | Minimed 780g |
| Phathom Pharmaceuticals, INC. | $38.00 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $30.90 | 2019-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $29.92 | 2019 | |
| Allergan, INC. | $28.73 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $28.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.48 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.42 | 2023 | Edarbi |
| Alexion Pharmaceuticals, INC. | $15.00 | 2021 | |
| Ge Healthcare | $14.35 | 2019 | |
| Sanofi Pasteur INC. | $13.86 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nickles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.